Direct Oral Anticoagulants (DOACs) Versus "New" Oral Anticoagulants (NOACs)?

Seminars in Hematology

Volumn 51, Issue 2, 2014, Pages 87-88

  Asmis, Lars M ^a  

^a Unilabs   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; DABIGATRAN; EDOXABAN; HIRUDIN; NEW DRUG; RIVAROXABAN; THROMBIN; XIMELAGATRAN;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BLEEDING; DRUG APPROVAL; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; HEART ATRIUM FIBRILLATION; HEPATITIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; AZETIDINES; BENZYLAMINES; HUMANS; MODELS, MOLECULAR; MORPHOLINES; TERMINOLOGY AS TOPIC; THIOPHENES; VITAMIN K;

EID: 84901333605     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2014.03.003     Document Type: Editorial

References (5)

1. Link K.P. The discovery of dicumarol and its sequels. Circulation 1959, 19:97-107.
2. Mannucci P.M., Poller L. Venous thrombosis and anticoagulant therapy. Br J Haematol 2001, 114:258-270.
3. Etminan M., Carleton B., Rochon P.A. Quantifying adverse drug events: are systematic reviews the answer?. Drug Safety 2004, 27:757-761.
4. Ansell J. Warfarin versus new agents: interpreting the data. Hematology Am Soc Hematol Educ Program 2010, 221-228.
5. Hoffman M., Monroe D.M. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. Semin Hematol 2001, 38(Suppl 12):6-9.